The Oncology Institute

The Oncology Institute, Inc. provides cancer care treatment services. It offers evidence-based cancer care to patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. The company is headquartered in Cerritos, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

The Oncology Institute reports strong revenue growth amidst operational challenges

TOI's Q1 2024 performance showcased robust revenue growth driven by strategic partnerships and record prescription sales, despite challenges with drug margin compression.
Operational achievements and a healthy cash position provide a strong foundation for TOI to navigate challenges and capitalize on growth opportunities in the oncology market.
By focusing on strategic priorities outlined by CEO Daniel Virnich, TOI aims to enhance profitability, expand market presence, and lead in value-based oncology care.

The Oncology Institute reports strong Q2 growth amid margin challenges

TOI's Q2 2024 earnings call reflected strong revenue growth but challenges with margins and profitability. The company is focused on addressing margin pressures and enhancing shareholder value through strategic initiatives.

The Oncology Institute reports robust Q3 growth and strategic focus

TOI's Q3 2024 performance reflects strong revenue growth, cost management, and strategic initiatives to drive operational efficiency and compliance.
The company's strengths lie in proactive cost optimization, expanded service offerings, and a clear strategic direction towards growth and performance.
Challenges include regulatory compliance, profitability sustainability, and ongoing efforts to balance financial flexibility with quality care delivery.
Opportunities abound in stable revenue streams, strategic partnerships, and enhanced profitability through optimized cost structures and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Oncology Institute, Inc. provides cancer care treatment services. It operates through the following business segments: Dispensary, Patient Care, and Clinical Trials and Other. The company was founded in 2007 and is headquartered in Cerritos, CA.

New program aims to improve patient outcomes, experience, and quality of life by streamlining access to affordable and high-quality oncology care New program aims to improve patient outcomes, experience, and quality of life by streamlining access to affordable and high-quality oncology care

Florida Blue enhances cancer care for thousands of members

Proof that Digital Transformation and Smarter Supply Chains Can Massively Cut Costs Proof that Digital Transformation and Smarter Supply Chains Can Massively Cut Costs

Grapevine Saves The Oncology Institute Millions On Healthcare Supplies

The Oncology Institute, Inc. (NASDAQ:TOI ) Q3 2024 Earnings Conference Call November 13, 2024 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO Rob Carter - CFO Operator Good afternoon and welcome to The Oncology Institute's Third Quarter 2024 Earnings Conference Call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q&A.

The Oncology Institute, Inc. (TOI) Q3 2024 Earnings Call Transcript

NEW YORK, NY / ACCESSWIRE / November 8, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology Institute, Inc.

NEW YORK, NY / ACCESSWIRE / November 7, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into The Oncology Institute, Inc.

NEW YORK, NY / ACCESSWIRE / November 6, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology

CERRITOS, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter 2024 financial results after the market close on Wednesday, November 13, 2024, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).

The Oncology Institute Announces Third Quarter 2024 Earnings Release Date and Conference Call

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into The Oncology Institute, Inc.

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology Institute, Inc

NEW YORK, NY / ACCESSWIRE / October 30, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology Institute, Inc.

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology Institute Inc.

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Partners, Inc.. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology Partners, Inc.

CERRITOS, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the nation, has joined Lantern's leading specialty care platform. Now, Lantern members will have access to cancer care at any of The Oncology Institute's state-of-the-art community clinics across 5 states.

The Oncology Institute Joins Lantern's Cancer Care Network of Excellence

NEW YORK, NY / ACCESSWIRE / October 3, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into The Oncology Institute-Inc.

Anchor value-based payor partnership leads to opening of locations in Portland and Salem Anchor value-based payor partnership leads to opening of locations in Portland and Salem

The Oncology Institute of Hope & Innovation Launches Oregon Market

NEW YORK, NY / ACCESSWIRE / August 29, 2024 / The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who own The Oncology Institute, Inc. ("TOI" or the "Company") (NASDAQ:TOI) stock purchased prior to November 9, 2021. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the acquisition of the company, then known as DFP Healthcare Acquisitions Corp. (DFPH), and whether the Board of TOI harmed stockholders, and whether all material facts had been properly disclosed to stockholders.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology Institute Inc

The Oncology Institute, Inc. (NASDAQ:TOI ) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Mark Hueppelsheuser – General Counsel Dan Virnich – Chief Executive Officer Mihir Shah – Chief Financial Officer Conference Call Participants Jack Slevin – Jefferies Operator Good afternoon, and welcome to The Oncology Institute Second Quarter 2024 Earnings Conference Call. Today's call is being recorded and we have allocated one hour for prepared remarks and Q&A.

The Oncology Institute, Inc. (TOI) Q2 2024 Earnings Call Transcript

The Oncology Institute, Inc. (TOI) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.19 per share a year ago.

The Oncology Institute, Inc. (TOI) Reports Q2 Loss, Misses Revenue Estimates

CERRITOS, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology practices in the country, today announced that Dr. Daniel Virnich, TOI's Chief Executive Officer, will participate at the following investor conferences:

The Oncology Institute to Participate at Upcoming Investor Conferences

CERRITOS, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Today, the Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) have announced their executives' participation in multiple panel presentations at the upcoming APG 2024 Spring Conference in San Diego. Chief Medical Officer, Dr. Yale Podnos, will be discussing artificial intelligence and its uses in an oncology practice in the breakout session panel “AI on the Front Lines: Improving Outcomes and Reducing Costs for Complex Patients”. Dr. Daniel Virnich, Chief Executive Officer, will join other industry leaders on another panel, “Assuming Global Risk for Pharmaceuticals.”

The Oncology Institute Executives to Participate in Multiple Panel Presentations at APG 2024 Spring Conference

The Oncology Institute, Inc. (NASDAQ:TOI ) Q1 2024 Earnings Conference Call May 14, 2024 5:00 PM ET Company Participants Dan Virnich - Chief Executive Officer Mihir Shah - Chief Financial Officer Conference Call Participants Jack Slevin - Jefferies Operator Good afternoon and welcome to The Oncology Institute's First Quarter 2024 Earnings Conference Call. Today's call is being recorded.

The Oncology Institute, Inc. (TOI) Q1 2024 Earnings Call Transcript

The Oncology Institute, Inc. (TOI) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.10 per share a year ago.

The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Lags Revenue Estimates

CERRITOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2024.

The Oncology Institute Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Guidance

CERRITOS, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) and Healthly, a rapidly growing healthcare company with over 180 primary care physicians, support services, and a focus on preventive medicine, have announced a strategic collaboration aimed at extending high-quality cancer care services to patients throughout Southern California. Commencing July 1, 2024, TOI will offer its cancer care services to patients affiliated with Healthly's medical groups and associated physicians across the region. Leveraging TOI's extensive network of oncology clinics and providers, this partnership aims to deliver convenient and comprehensive cancer care services to patients within the Healthly network.

News for The Oncology Institute Stock (TOI)